National Asset Management, Inc. Exact Sciences Corp Transaction History

National Asset Management, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$56.27 - $73.77 $29,541 - $38,729	525 Added 15.89%	3,829 $264,000
Q4 2023 Mar 15, 2024	SELL	$59.06 - $75.72 $31,006 - $39,753	-525 Reduced 13.71%	3,304 $244,000
Q3 2023 Dec 01, 2023	SELL	$65.94 - $99.04 $36,596 - $54,967	-555 Reduced 12.66%	3,829 $261,000
Q2 2023 Jul 27, 2023	BUY	$62.68 - $95.05 $274,789 - $416,699	4,384 New	4,384 $411,000
Q2 2022 Aug 12, 2022	SELL	$35.61 - $76.23 $160,031 - $342,577	-4,494 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$57.56 - $82.54 $16,922 - $24,266	-294 Reduced 6.14%	4,494 $315,000
Q4 2021 Jan 28, 2022	SELL	$72.5 - $100.68 $19,720 - $27,384	-272 Reduced 5.38%	4,788 $373,000
Q3 2021 Nov 16, 2021	SELL	$90.24 - $124.05 $2,256 - $3,101	-25 Reduced 0.49%	5,060 $504,000
Q2 2021 Aug 10, 2021	SELL	$93.66 - $139.27 $115,201 - $171,302	-1,230 Reduced 19.48%	5,085 $638,000
Q1 2021 May 13, 2021	BUY	$116.57 - $155.01 $210,875 - $280,413	1,809 Added 40.15%	6,315 $833,000
Q4 2020 Feb 04, 2021	SELL	$99.61 - $142.12 $49,705 - $70,917	-499 Reduced 9.97%	4,506 $597,000
Q3 2020 Nov 09, 2020	BUY	$72.92 - $102.01 $68,982 - $96,501	946 Added 23.31%	5,005 $499,000
Q2 2020 Jul 31, 2020	BUY	$55.75 - $92.75 $226,289 - $376,472	4,059 New	4,059 $353,000
Q2 2019 Aug 05, 2019	SELL	$89.51 - $118.04 $383,818 - $506,155	-4,288 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$61.98 - $96.5 $21,259 - $33,099	343 Added 8.69%	4,288 $372,000
Q4 2018 Feb 08, 2019	BUY	$56.04 - $82.66 $221,077 - $326,093	3,945 New	3,945 $249,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.